The company's pipeline focused on specialized cardiovascular treatments, with bentracimab (PB2452) as its lead candidate, a reversal agent for the antiplatelet drug ticagrelor. Prior to bankruptcy, PhaseBio had received FDA Breakthrough Therapy designation for its lead program but was unable to successfully advance or commercialize its assets.
Cyborg Score Rationale
The company entered liquidation bankruptcy in September 2024 after failing to advance its pipeline sufficiently or secure adequate funding. All operations have ceased and the company is no longer a going concern.
Top Insights
Company ceased operations September 30, 2024 under Chapter 11 bankruptcy liquidation
Lead candidate bentracimab received FDA Breakthrough Therapy designation but failed to reach successful commercialization
Pipeline included pemziviptadil (PB1046) for vasodilatory indications in addition to cardiovascular focus
Stock now trades OTC as PHASQ after delisting from NASDAQ
Named Competitors
Cardiovascular Therapeutics Portfolio — Established cardiovascular drug developer
Anticoagulation Solutions — Specialized in anticoagulant reversal
Recent Developments
(September 2024) Company filed Chapter 11 bankruptcy and ceased operations
(Pre-2024) FDA Breakthrough Therapy designation granted to lead program bentracimab
Open the full interactive PhaseBio Pharmaceuticals Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.